• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia

    6/25/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care
    Get the next $INBS alert in real time by email

    NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, non-invasive drug screening solutions, today announced the success of its ongoing partnership with Spjotgard, an established distributor serving the Scandinavian market. The collaboration is accelerating the adoption of the Intelligent Fingerprinting Drug Screening System across Sweden, Norway, and Denmark, with a growing interest in Finland.

    Spjotgard, founded in 2021 by a team with deep pharmaceutical expertise, has rapidly developed a strong regional footprint, positioning INBS' fingerprint drug testing technology as its flagship solution in response to rising demand for modern, dignified approaches to drug testing.

    "From the very beginning, we've seen strong interest in fingerprint-based testing across the region," said Hans Svensson, joint owner of Spjotgard. "Traditional methods like saliva and urine are still common, but our customers, especially in workplace safety and education, are seeking more hygienic, easy to use and less invasive alternatives. Fingerprint drug testing delivers that while delivering comparable levels of accuracy, saving time and reducing disruption."

    INBS' Drug Screening System is primarily used for random testing, post-incident investigations, and for-cause testing scenarios. Customers appreciate its simplicity and reduced discomfort compared to traditional urine tests, which require invasive observation. INBS' Drug Screening System is used across logistics, construction, warehousing, education, and the criminal justice sector. In Sweden, growing concern about drug driving incidents and drug misuse among youth is leading organizations to explore more proactive testing strategies.

    Spjotgard's presence in the region continues to expand through strategic collaborations with providers of drug-detection dogs and alcohol testing services. This includes a partner that has manufactured and sold evidential alcohol testing instruments to judicial authorities, primarily in the Nordic countries, as well as entry systems for companies with automatic alcohol checks. Spjotgard is actively engaged in customer demonstrations and industry events, primarily in Sweden. Spjotgard sees significant potential in Norway and plans to aggressively target this region in the months ahead.

    "Scandinavia is setting a high standard in progressive drug testing policy, particularly Sweden, which is often seen as a model for neighboring countries," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. "Spjotgard's strong market knowledge and trusted relationships make them a valuable partner as we continue to scale across Northern Europe."

    INBS' Drug Screening System enables rapid, on-site drug screening using fingerprint sweat, with results delivered in under 10 minutes. Unlike traditional methods that require supervision, third-party administration, or removing staff from the job, INBS' Drug Screening System offers a discreet and efficient solution that is quickly gaining favor among HR teams, health and safety managers, and union representatives in Scandinavia.

    With over 450 accounts across 24 countries, INBS continues to advance the evolution of drug screening technology. INBS and Spjotgard are driving a global shift towards more progressive, dignified, and effective drug testing solutions that satisfy the needs of employers in Scandinavia and beyond.

    About Spjotgard

    Spjotgard is a Scandinavian distributor of workplace drug testing solutions, operating across Sweden, Norway, and Denmark. Founded in 2021 by five part-owners, the company offers strategic solutions to meet the safety and compliance needs of employers, educational institutions, and public sector agencies throughout the region.

    As a dynamic start-up, Spjotgard is dedicated to marketing and distributing innovative, high-quality, and market-leading products. Its carefully selected portfolio includes life science solutions and high-tech products for targeted sectors. With a blend of strategic insight and technical expertise, Spjotgard is positioned to deliver exceptional value to its partners and customers.

    About Intelligent Bio Solutions Inc.

    Intelligent Bio Solutions Inc. (NASDAQ:INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

    For more information, visit: https://www.ibs.inc

    Forward-Looking Statements: 

    Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

    Company Contact:

    Intelligent Bio Solutions Inc.

    [email protected]

    LinkedIn | Twitter

    Investor & Media Contact:

    Valter Pinto, Managing Director

    KCSA Strategic Communications

    PH: (212) 896-1254

    [email protected]



    Primary Logo

    Get the next $INBS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INBS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $INBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

      4/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

      3/31/25 4:15:27 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Simeonidis Harry was granted 40,000 shares, increasing direct ownership by 9,804% to 40,408 units (SEC Form 4)

      4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

      9/27/24 5:00:16 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Sakiris Spiro Kevin was granted 34,500 shares, increasing direct ownership by 10,952% to 34,815 units (SEC Form 4)

      4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

      9/27/24 5:00:15 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia

      NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, non-invasive drug screening solutions, today announced the success of its ongoing partnership with Spjotgard, an established distributor serving the Scandinavian market. The collaboration is accelerating the adoption of the Intelligent Fingerprinting Drug Screening System across Sweden, Norway, and Denmark, with a growing interest in Finland. Spjotgard, founded in 2021 by a team with deep pharmaceutical expertise, has rapidly developed a strong regional footprint, positioning INBS' fingerprint drug testing technology as it

      6/25/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Launches In-House Fingerprint Drug Testing Across 20+ Sites for Major Australian Waste Operator, Accelerating APAC Expansion

      NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Managed Waste Service ("MWS"), a leading Australian waste management provider, plans to implement INBS' Intelligent Fingerprinting Drug Screening System across its New South Wales operations, including its land clearing and green waste processing sites. The decision marks MWS's first move into in-house drug testing across multiple locations, with more than 20 sites simultaneously engaged in remote testing operations. MWS plans to conduct pre-employment, random, an

      6/18/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • IBN Announces Latest Episode of The BioMedWire Podcast Featuring Harry Simeonidis, President and CEO of Intelligent Bio Solutions Inc.

      AUSTIN, Texas, June 17, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Harry Simeonidis, CEO of Intelligent Bio Solutions Inc. (NASDAQ:INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions. D

      6/17/25 8:00:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    SEC Filings

    See more
    • Intelligent Bio Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

      7/3/25 4:15:34 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Intelligent Bio Solutions Inc.

      S-8 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

      5/30/25 5:26:11 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

      5/16/25 8:00:18 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    Financials

    Live finance-specific insights

    See more
    • Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

      20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025  35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal third quarter and nine months ended March 31, 2025, and provided a business update.   The Company delivered a st

      5/13/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements

      Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal second quarter and six

      2/13/25 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

      - Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2024, and provided a business update. Fiscal fourth quarter revenue totalled $0.73 million, an increase of 64% compared to the same period the prior year, and full-year revenue totalled $3.11 million,

      9/19/24 8:30:00 AM ET
      $INBS
      Medical/Dental Instruments
      Health Care

    $INBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

      SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

      11/14/24 7:16:17 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

      SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

      11/14/24 4:31:30 PM ET
      $INBS
      Medical/Dental Instruments
      Health Care